Global Bispecific Antibody Molecular Drug Market Growth 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
LPI (LP Information)' newest research report, the “Bispecific Antibody Molecular Drug Industry Forecast” looks at past sales and reviews total world Bispecific Antibody Molecular Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Bispecific Antibody Molecular Drug sales for 2023 through 2029. With Bispecific Antibody Molecular Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bispecific Antibody Molecular Drug industry.
This Insight Report provides a comprehensive analysis of the global Bispecific Antibody Molecular Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bispecific Antibody Molecular Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bispecific Antibody Molecular Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bispecific Antibody Molecular Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bispecific Antibody Molecular Drug.
The global Bispecific Antibody Molecular Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bispecific Antibody Molecular Drug players cover MacroGenics, Xencor, Medimmune, Merrimsck, Merus NV, Genentech, Zhongshan Kangfang Biology Medicine, Sichuan Baili Pharmaceutical and Alphamab Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bispecific Antibody Molecular Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
What is the 10-year outlook for the global Bispecific Antibody Molecular Drug market?
What factors are driving Bispecific Antibody Molecular Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bispecific Antibody Molecular Drug market opportunities vary by end market size?
How does Bispecific Antibody Molecular Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Bispecific Antibody Molecular Drug Industry Forecast” looks at past sales and reviews total world Bispecific Antibody Molecular Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Bispecific Antibody Molecular Drug sales for 2023 through 2029. With Bispecific Antibody Molecular Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bispecific Antibody Molecular Drug industry.
This Insight Report provides a comprehensive analysis of the global Bispecific Antibody Molecular Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bispecific Antibody Molecular Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Bispecific Antibody Molecular Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bispecific Antibody Molecular Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bispecific Antibody Molecular Drug.
The global Bispecific Antibody Molecular Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Bispecific Antibody Molecular Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Bispecific Antibody Molecular Drug players cover MacroGenics, Xencor, Medimmune, Merrimsck, Merus NV, Genentech, Zhongshan Kangfang Biology Medicine, Sichuan Baili Pharmaceutical and Alphamab Oncology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Bispecific Antibody Molecular Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- EGFR?HER3 Target
- PD-1?CTLA-4 Target
- HER2?HER3 Target
- Pancreatic Cancer
- Breast Cancer
- Colorectal Cancer
- Non-Small Cell Lung Cancer
- Solid Tumor
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- MacroGenics
- Xencor
- Medimmune
- Merrimsck
- Merus NV
- Genentech
- Zhongshan Kangfang Biology Medicine
- Sichuan Baili Pharmaceutical
- Alphamab Oncology
What is the 10-year outlook for the global Bispecific Antibody Molecular Drug market?
What factors are driving Bispecific Antibody Molecular Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Bispecific Antibody Molecular Drug market opportunities vary by end market size?
How does Bispecific Antibody Molecular Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Bispecific Antibody Molecular Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Bispecific Antibody Molecular Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Bispecific Antibody Molecular Drug by Country/Region, 2018, 2022 & 2029
2.2 Bispecific Antibody Molecular Drug Segment by Type
2.2.1 EGFR?HER3 Target
2.2.2 PD-1?CTLA-4 Target
2.2.3 HER2?HER3 Target
2.3 Bispecific Antibody Molecular Drug Sales by Type
2.3.1 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Bispecific Antibody Molecular Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Bispecific Antibody Molecular Drug Sale Price by Type (2018-2023)
2.4 Bispecific Antibody Molecular Drug Segment by Application
2.4.1 Pancreatic Cancer
2.4.2 Breast Cancer
2.4.3 Colorectal Cancer
2.4.4 Non-Small Cell Lung Cancer
2.4.5 Solid Tumor
2.4.6 Others
2.5 Bispecific Antibody Molecular Drug Sales by Application
2.5.1 Global Bispecific Antibody Molecular Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Bispecific Antibody Molecular Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Bispecific Antibody Molecular Drug Sale Price by Application (2018-2023)
3 GLOBAL BISPECIFIC ANTIBODY MOLECULAR DRUG BY COMPANY
3.1 Global Bispecific Antibody Molecular Drug Breakdown Data by Company
3.1.1 Global Bispecific Antibody Molecular Drug Annual Sales by Company (2018-2023)
3.1.2 Global Bispecific Antibody Molecular Drug Sales Market Share by Company (2018-2023)
3.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Bispecific Antibody Molecular Drug Revenue by Company (2018-2023)
3.2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Company (2018-2023)
3.3 Global Bispecific Antibody Molecular Drug Sale Price by Company
3.4 Key Manufacturers Bispecific Antibody Molecular Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bispecific Antibody Molecular Drug Product Location Distribution
3.4.2 Players Bispecific Antibody Molecular Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BISPECIFIC ANTIBODY MOLECULAR DRUG BY GEOGRAPHIC REGION
4.1 World Historic Bispecific Antibody Molecular Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Bispecific Antibody Molecular Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Bispecific Antibody Molecular Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Bispecific Antibody Molecular Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Bispecific Antibody Molecular Drug Sales Growth
4.4 APAC Bispecific Antibody Molecular Drug Sales Growth
4.5 Europe Bispecific Antibody Molecular Drug Sales Growth
4.6 Middle East & Africa Bispecific Antibody Molecular Drug Sales Growth
5 AMERICAS
5.1 Americas Bispecific Antibody Molecular Drug Sales by Country
5.1.1 Americas Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
5.1.2 Americas Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
5.2 Americas Bispecific Antibody Molecular Drug Sales by Type
5.3 Americas Bispecific Antibody Molecular Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bispecific Antibody Molecular Drug Sales by Region
6.1.1 APAC Bispecific Antibody Molecular Drug Sales by Region (2018-2023)
6.1.2 APAC Bispecific Antibody Molecular Drug Revenue by Region (2018-2023)
6.2 APAC Bispecific Antibody Molecular Drug Sales by Type
6.3 APAC Bispecific Antibody Molecular Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Bispecific Antibody Molecular Drug by Country
7.1.1 Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
7.1.2 Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
7.2 Europe Bispecific Antibody Molecular Drug Sales by Type
7.3 Europe Bispecific Antibody Molecular Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Bispecific Antibody Molecular Drug by Country
8.1.1 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Type
8.3 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bispecific Antibody Molecular Drug
10.3 Manufacturing Process Analysis of Bispecific Antibody Molecular Drug
10.4 Industry Chain Structure of Bispecific Antibody Molecular Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bispecific Antibody Molecular Drug Distributors
11.3 Bispecific Antibody Molecular Drug Customer
12 WORLD FORECAST REVIEW FOR BISPECIFIC ANTIBODY MOLECULAR DRUG BY GEOGRAPHIC REGION
12.1 Global Bispecific Antibody Molecular Drug Market Size Forecast by Region
12.1.1 Global Bispecific Antibody Molecular Drug Forecast by Region (2024-2029)
12.1.2 Global Bispecific Antibody Molecular Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Bispecific Antibody Molecular Drug Forecast by Type
12.7 Global Bispecific Antibody Molecular Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 MacroGenics
13.1.1 MacroGenics Company Information
13.1.2 MacroGenics Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 MacroGenics Main Business Overview
13.1.5 MacroGenics Latest Developments
13.2 Xencor
13.2.1 Xencor Company Information
13.2.2 Xencor Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Xencor Main Business Overview
13.2.5 Xencor Latest Developments
13.3 Medimmune
13.3.1 Medimmune Company Information
13.3.2 Medimmune Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Medimmune Main Business Overview
13.3.5 Medimmune Latest Developments
13.4 Merrimsck
13.4.1 Merrimsck Company Information
13.4.2 Merrimsck Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merrimsck Main Business Overview
13.4.5 Merrimsck Latest Developments
13.5 Merus NV
13.5.1 Merus NV Company Information
13.5.2 Merus NV Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merus NV Main Business Overview
13.5.5 Merus NV Latest Developments
13.6 Genentech
13.6.1 Genentech Company Information
13.6.2 Genentech Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Genentech Main Business Overview
13.6.5 Genentech Latest Developments
13.7 Zhongshan Kangfang Biology Medicine
13.7.1 Zhongshan Kangfang Biology Medicine Company Information
13.7.2 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.7.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Zhongshan Kangfang Biology Medicine Main Business Overview
13.7.5 Zhongshan Kangfang Biology Medicine Latest Developments
13.8 Sichuan Baili Pharmaceutical
13.8.1 Sichuan Baili Pharmaceutical Company Information
13.8.2 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sichuan Baili Pharmaceutical Main Business Overview
13.8.5 Sichuan Baili Pharmaceutical Latest Developments
13.9 Alphamab Oncology
13.9.1 Alphamab Oncology Company Information
13.9.2 Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Alphamab Oncology Main Business Overview
13.9.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Bispecific Antibody Molecular Drug Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Bispecific Antibody Molecular Drug by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Bispecific Antibody Molecular Drug by Country/Region, 2018, 2022 & 2029
2.2 Bispecific Antibody Molecular Drug Segment by Type
2.2.1 EGFR?HER3 Target
2.2.2 PD-1?CTLA-4 Target
2.2.3 HER2?HER3 Target
2.3 Bispecific Antibody Molecular Drug Sales by Type
2.3.1 Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
2.3.2 Global Bispecific Antibody Molecular Drug Revenue and Market Share by Type (2018-2023)
2.3.3 Global Bispecific Antibody Molecular Drug Sale Price by Type (2018-2023)
2.4 Bispecific Antibody Molecular Drug Segment by Application
2.4.1 Pancreatic Cancer
2.4.2 Breast Cancer
2.4.3 Colorectal Cancer
2.4.4 Non-Small Cell Lung Cancer
2.4.5 Solid Tumor
2.4.6 Others
2.5 Bispecific Antibody Molecular Drug Sales by Application
2.5.1 Global Bispecific Antibody Molecular Drug Sale Market Share by Application (2018-2023)
2.5.2 Global Bispecific Antibody Molecular Drug Revenue and Market Share by Application (2018-2023)
2.5.3 Global Bispecific Antibody Molecular Drug Sale Price by Application (2018-2023)
3 GLOBAL BISPECIFIC ANTIBODY MOLECULAR DRUG BY COMPANY
3.1 Global Bispecific Antibody Molecular Drug Breakdown Data by Company
3.1.1 Global Bispecific Antibody Molecular Drug Annual Sales by Company (2018-2023)
3.1.2 Global Bispecific Antibody Molecular Drug Sales Market Share by Company (2018-2023)
3.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Company (2018-2023)
3.2.1 Global Bispecific Antibody Molecular Drug Revenue by Company (2018-2023)
3.2.2 Global Bispecific Antibody Molecular Drug Revenue Market Share by Company (2018-2023)
3.3 Global Bispecific Antibody Molecular Drug Sale Price by Company
3.4 Key Manufacturers Bispecific Antibody Molecular Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Bispecific Antibody Molecular Drug Product Location Distribution
3.4.2 Players Bispecific Antibody Molecular Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR BISPECIFIC ANTIBODY MOLECULAR DRUG BY GEOGRAPHIC REGION
4.1 World Historic Bispecific Antibody Molecular Drug Market Size by Geographic Region (2018-2023)
4.1.1 Global Bispecific Antibody Molecular Drug Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Bispecific Antibody Molecular Drug Market Size by Country/Region (2018-2023)
4.2.1 Global Bispecific Antibody Molecular Drug Annual Sales by Country/Region (2018-2023)
4.2.2 Global Bispecific Antibody Molecular Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Bispecific Antibody Molecular Drug Sales Growth
4.4 APAC Bispecific Antibody Molecular Drug Sales Growth
4.5 Europe Bispecific Antibody Molecular Drug Sales Growth
4.6 Middle East & Africa Bispecific Antibody Molecular Drug Sales Growth
5 AMERICAS
5.1 Americas Bispecific Antibody Molecular Drug Sales by Country
5.1.1 Americas Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
5.1.2 Americas Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
5.2 Americas Bispecific Antibody Molecular Drug Sales by Type
5.3 Americas Bispecific Antibody Molecular Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Bispecific Antibody Molecular Drug Sales by Region
6.1.1 APAC Bispecific Antibody Molecular Drug Sales by Region (2018-2023)
6.1.2 APAC Bispecific Antibody Molecular Drug Revenue by Region (2018-2023)
6.2 APAC Bispecific Antibody Molecular Drug Sales by Type
6.3 APAC Bispecific Antibody Molecular Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Bispecific Antibody Molecular Drug by Country
7.1.1 Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
7.1.2 Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
7.2 Europe Bispecific Antibody Molecular Drug Sales by Type
7.3 Europe Bispecific Antibody Molecular Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Bispecific Antibody Molecular Drug by Country
8.1.1 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2023)
8.1.2 Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Type
8.3 Middle East & Africa Bispecific Antibody Molecular Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bispecific Antibody Molecular Drug
10.3 Manufacturing Process Analysis of Bispecific Antibody Molecular Drug
10.4 Industry Chain Structure of Bispecific Antibody Molecular Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Bispecific Antibody Molecular Drug Distributors
11.3 Bispecific Antibody Molecular Drug Customer
12 WORLD FORECAST REVIEW FOR BISPECIFIC ANTIBODY MOLECULAR DRUG BY GEOGRAPHIC REGION
12.1 Global Bispecific Antibody Molecular Drug Market Size Forecast by Region
12.1.1 Global Bispecific Antibody Molecular Drug Forecast by Region (2024-2029)
12.1.2 Global Bispecific Antibody Molecular Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Bispecific Antibody Molecular Drug Forecast by Type
12.7 Global Bispecific Antibody Molecular Drug Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 MacroGenics
13.1.1 MacroGenics Company Information
13.1.2 MacroGenics Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.1.3 MacroGenics Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 MacroGenics Main Business Overview
13.1.5 MacroGenics Latest Developments
13.2 Xencor
13.2.1 Xencor Company Information
13.2.2 Xencor Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.2.3 Xencor Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Xencor Main Business Overview
13.2.5 Xencor Latest Developments
13.3 Medimmune
13.3.1 Medimmune Company Information
13.3.2 Medimmune Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.3.3 Medimmune Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Medimmune Main Business Overview
13.3.5 Medimmune Latest Developments
13.4 Merrimsck
13.4.1 Merrimsck Company Information
13.4.2 Merrimsck Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.4.3 Merrimsck Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Merrimsck Main Business Overview
13.4.5 Merrimsck Latest Developments
13.5 Merus NV
13.5.1 Merus NV Company Information
13.5.2 Merus NV Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.5.3 Merus NV Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merus NV Main Business Overview
13.5.5 Merus NV Latest Developments
13.6 Genentech
13.6.1 Genentech Company Information
13.6.2 Genentech Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.6.3 Genentech Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Genentech Main Business Overview
13.6.5 Genentech Latest Developments
13.7 Zhongshan Kangfang Biology Medicine
13.7.1 Zhongshan Kangfang Biology Medicine Company Information
13.7.2 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.7.3 Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Zhongshan Kangfang Biology Medicine Main Business Overview
13.7.5 Zhongshan Kangfang Biology Medicine Latest Developments
13.8 Sichuan Baili Pharmaceutical
13.8.1 Sichuan Baili Pharmaceutical Company Information
13.8.2 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.8.3 Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sichuan Baili Pharmaceutical Main Business Overview
13.8.5 Sichuan Baili Pharmaceutical Latest Developments
13.9 Alphamab Oncology
13.9.1 Alphamab Oncology Company Information
13.9.2 Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolios and Specifications
13.9.3 Alphamab Oncology Bispecific Antibody Molecular Drug Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Alphamab Oncology Main Business Overview
13.9.5 Alphamab Oncology Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Bispecific Antibody Molecular Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Bispecific Antibody Molecular Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of EGFR?HER3 Target
Table 4. Major Players of PD-1?CTLA-4 Target
Table 5. Major Players of HER2?HER3 Target
Table 6. Global Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 7. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Table 8. Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2023) & ($ million)
Table 9. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2023)
Table 10. Global Bispecific Antibody Molecular Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 12. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Table 13. Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2023)
Table 14. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2023)
Table 15. Global Bispecific Antibody Molecular Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Bispecific Antibody Molecular Drug Sales by Company (2018-2023) & (K Units)
Table 17. Global Bispecific Antibody Molecular Drug Sales Market Share by Company (2018-2023)
Table 18. Global Bispecific Antibody Molecular Drug Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Bispecific Antibody Molecular Drug Revenue Market Share by Company (2018-2023)
Table 20. Global Bispecific Antibody Molecular Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Bispecific Antibody Molecular Drug Producing Area Distribution and Sales Area
Table 22. Players Bispecific Antibody Molecular Drug Products Offered
Table 23. Bispecific Antibody Molecular Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Bispecific Antibody Molecular Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Bispecific Antibody Molecular Drug Sales Market Share Geographic Region (2018-2023)
Table 28. Global Bispecific Antibody Molecular Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Bispecific Antibody Molecular Drug Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Bispecific Antibody Molecular Drug Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Bispecific Antibody Molecular Drug Sales Market Share by Country/Region (2018-2023)
Table 32. Global Bispecific Antibody Molecular Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Bispecific Antibody Molecular Drug Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 35. Americas Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 36. Americas Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 38. Americas Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 39. Americas Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 40. APAC Bispecific Antibody Molecular Drug Sales by Region (2018-2023) & (K Units)
Table 41. APAC Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2023)
Table 42. APAC Bispecific Antibody Molecular Drug Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2023)
Table 44. APAC Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 45. APAC Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 46. Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 47. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 48. Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 50. Europe Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 51. Europe Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Bispecific Antibody Molecular Drug
Table 59. Key Market Challenges & Risks of Bispecific Antibody Molecular Drug
Table 60. Key Industry Trends of Bispecific Antibody Molecular Drug
Table 61. Bispecific Antibody Molecular Drug Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Bispecific Antibody Molecular Drug Distributors List
Table 64. Bispecific Antibody Molecular Drug Customer List
Table 65. Global Bispecific Antibody Molecular Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Bispecific Antibody Molecular Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Bispecific Antibody Molecular Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Bispecific Antibody Molecular Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Bispecific Antibody Molecular Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Bispecific Antibody Molecular Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Bispecific Antibody Molecular Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Bispecific Antibody Molecular Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. MacroGenics Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. MacroGenics Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 81. MacroGenics Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. MacroGenics Main Business
Table 83. MacroGenics Latest Developments
Table 84. Xencor Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Xencor Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 86. Xencor Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Xencor Main Business
Table 88. Xencor Latest Developments
Table 89. Medimmune Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Medimmune Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 91. Medimmune Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Medimmune Main Business
Table 93. Medimmune Latest Developments
Table 94. Merrimsck Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Merrimsck Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 96. Merrimsck Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Merrimsck Main Business
Table 98. Merrimsck Latest Developments
Table 99. Merus NV Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Merus NV Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 101. Merus NV Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Merus NV Main Business
Table 103. Merus NV Latest Developments
Table 104. Genentech Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Genentech Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 106. Genentech Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Genentech Main Business
Table 108. Genentech Latest Developments
Table 109. Zhongshan Kangfang Biology Medicine Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 111. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Zhongshan Kangfang Biology Medicine Main Business
Table 113. Zhongshan Kangfang Biology Medicine Latest Developments
Table 114. Sichuan Baili Pharmaceutical Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 116. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Sichuan Baili Pharmaceutical Main Business
Table 118. Sichuan Baili Pharmaceutical Latest Developments
Table 119. Alphamab Oncology Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 121. Alphamab Oncology Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Alphamab Oncology Main Business
Table 123. Alphamab Oncology Latest Developments
Table 1. Bispecific Antibody Molecular Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Bispecific Antibody Molecular Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of EGFR?HER3 Target
Table 4. Major Players of PD-1?CTLA-4 Target
Table 5. Major Players of HER2?HER3 Target
Table 6. Global Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 7. Global Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Table 8. Global Bispecific Antibody Molecular Drug Revenue by Type (2018-2023) & ($ million)
Table 9. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2023)
Table 10. Global Bispecific Antibody Molecular Drug Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 12. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Table 13. Global Bispecific Antibody Molecular Drug Revenue by Application (2018-2023)
Table 14. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application (2018-2023)
Table 15. Global Bispecific Antibody Molecular Drug Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Bispecific Antibody Molecular Drug Sales by Company (2018-2023) & (K Units)
Table 17. Global Bispecific Antibody Molecular Drug Sales Market Share by Company (2018-2023)
Table 18. Global Bispecific Antibody Molecular Drug Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Bispecific Antibody Molecular Drug Revenue Market Share by Company (2018-2023)
Table 20. Global Bispecific Antibody Molecular Drug Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Bispecific Antibody Molecular Drug Producing Area Distribution and Sales Area
Table 22. Players Bispecific Antibody Molecular Drug Products Offered
Table 23. Bispecific Antibody Molecular Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Bispecific Antibody Molecular Drug Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Bispecific Antibody Molecular Drug Sales Market Share Geographic Region (2018-2023)
Table 28. Global Bispecific Antibody Molecular Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Bispecific Antibody Molecular Drug Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Bispecific Antibody Molecular Drug Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Bispecific Antibody Molecular Drug Sales Market Share by Country/Region (2018-2023)
Table 32. Global Bispecific Antibody Molecular Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Bispecific Antibody Molecular Drug Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 35. Americas Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 36. Americas Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 38. Americas Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 39. Americas Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 40. APAC Bispecific Antibody Molecular Drug Sales by Region (2018-2023) & (K Units)
Table 41. APAC Bispecific Antibody Molecular Drug Sales Market Share by Region (2018-2023)
Table 42. APAC Bispecific Antibody Molecular Drug Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Bispecific Antibody Molecular Drug Revenue Market Share by Region (2018-2023)
Table 44. APAC Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 45. APAC Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 46. Europe Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 47. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 48. Europe Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 50. Europe Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 51. Europe Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Bispecific Antibody Molecular Drug Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Bispecific Antibody Molecular Drug Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Bispecific Antibody Molecular Drug
Table 59. Key Market Challenges & Risks of Bispecific Antibody Molecular Drug
Table 60. Key Industry Trends of Bispecific Antibody Molecular Drug
Table 61. Bispecific Antibody Molecular Drug Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Bispecific Antibody Molecular Drug Distributors List
Table 64. Bispecific Antibody Molecular Drug Customer List
Table 65. Global Bispecific Antibody Molecular Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Bispecific Antibody Molecular Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Bispecific Antibody Molecular Drug Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Bispecific Antibody Molecular Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Bispecific Antibody Molecular Drug Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Bispecific Antibody Molecular Drug Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Bispecific Antibody Molecular Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Bispecific Antibody Molecular Drug Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Bispecific Antibody Molecular Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. MacroGenics Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 80. MacroGenics Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 81. MacroGenics Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. MacroGenics Main Business
Table 83. MacroGenics Latest Developments
Table 84. Xencor Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 85. Xencor Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 86. Xencor Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Xencor Main Business
Table 88. Xencor Latest Developments
Table 89. Medimmune Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 90. Medimmune Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 91. Medimmune Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Medimmune Main Business
Table 93. Medimmune Latest Developments
Table 94. Merrimsck Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 95. Merrimsck Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 96. Merrimsck Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Merrimsck Main Business
Table 98. Merrimsck Latest Developments
Table 99. Merus NV Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 100. Merus NV Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 101. Merus NV Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Merus NV Main Business
Table 103. Merus NV Latest Developments
Table 104. Genentech Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 105. Genentech Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 106. Genentech Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Genentech Main Business
Table 108. Genentech Latest Developments
Table 109. Zhongshan Kangfang Biology Medicine Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 110. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 111. Zhongshan Kangfang Biology Medicine Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Zhongshan Kangfang Biology Medicine Main Business
Table 113. Zhongshan Kangfang Biology Medicine Latest Developments
Table 114. Sichuan Baili Pharmaceutical Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 115. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 116. Sichuan Baili Pharmaceutical Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Sichuan Baili Pharmaceutical Main Business
Table 118. Sichuan Baili Pharmaceutical Latest Developments
Table 119. Alphamab Oncology Basic Information, Bispecific Antibody Molecular Drug Manufacturing Base, Sales Area and Its Competitors
Table 120. Alphamab Oncology Bispecific Antibody Molecular Drug Product Portfolios and Specifications
Table 121. Alphamab Oncology Bispecific Antibody Molecular Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Alphamab Oncology Main Business
Table 123. Alphamab Oncology Latest Developments
LIST OF FIGURES
Figure 1. Picture of Bispecific Antibody Molecular Drug
Figure 2. Bispecific Antibody Molecular Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bispecific Antibody Molecular Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Bispecific Antibody Molecular Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Bispecific Antibody Molecular Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of EGFR?HER3 Target
Figure 10. Product Picture of PD-1?CTLA-4 Target
Figure 11. Product Picture of HER2?HER3 Target
Figure 12. Global Bispecific Antibody Molecular Drug Sales Market Share by Type in 2022
Figure 13. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2023)
Figure 14. Bispecific Antibody Molecular Drug Consumed in Pancreatic Cancer
Figure 15. Global Bispecific Antibody Molecular Drug Market: Pancreatic Cancer (2018-2023) & (K Units)
Figure 16. Bispecific Antibody Molecular Drug Consumed in Breast Cancer
Figure 17. Global Bispecific Antibody Molecular Drug Market: Breast Cancer (2018-2023) & (K Units)
Figure 18. Bispecific Antibody Molecular Drug Consumed in Colorectal Cancer
Figure 19. Global Bispecific Antibody Molecular Drug Market: Colorectal Cancer (2018-2023) & (K Units)
Figure 20. Bispecific Antibody Molecular Drug Consumed in Non-Small Cell Lung Cancer
Figure 21. Global Bispecific Antibody Molecular Drug Market: Non-Small Cell Lung Cancer (2018-2023) & (K Units)
Figure 22. Bispecific Antibody Molecular Drug Consumed in Solid Tumor
Figure 23. Global Bispecific Antibody Molecular Drug Market: Solid Tumor (2018-2023) & (K Units)
Figure 24. Bispecific Antibody Molecular Drug Consumed in Others
Figure 25. Global Bispecific Antibody Molecular Drug Market: Others (2018-2023) & (K Units)
Figure 26. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2022)
Figure 27. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application in 2022
Figure 28. Bispecific Antibody Molecular Drug Sales Market by Company in 2022 (K Units)
Figure 29. Global Bispecific Antibody Molecular Drug Sales Market Share by Company in 2022
Figure 30. Bispecific Antibody Molecular Drug Revenue Market by Company in 2022 ($ Million)
Figure 31. Global Bispecific Antibody Molecular Drug Revenue Market Share by Company in 2022
Figure 32. Global Bispecific Antibody Molecular Drug Sales Market Share by Geographic Region (2018-2023)
Figure 33. Global Bispecific Antibody Molecular Drug Revenue Market Share by Geographic Region in 2022
Figure 34. Americas Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 35. Americas Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 36. APAC Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 37. APAC Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 38. Europe Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 39. Europe Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 40. Middle East & Africa Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 41. Middle East & Africa Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 42. Americas Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 43. Americas Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 44. Americas Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 45. Americas Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 46. United States Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 47. Canada Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. Mexico Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. Brazil Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. APAC Bispecific Antibody Molecular Drug Sales Market Share by Region in 2022
Figure 51. APAC Bispecific Antibody Molecular Drug Revenue Market Share by Regions in 2022
Figure 52. APAC Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 53. APAC Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 54. China Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Japan Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. South Korea Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. Southeast Asia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 58. India Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. Australia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. China Taiwan Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 62. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 63. Europe Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 64. Europe Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 65. Germany Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. France Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 67. UK Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. Italy Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. Russia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 71. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 72. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 73. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 74. Egypt Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 75. South Africa Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 76. Israel Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 77. Turkey Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 78. GCC Country Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 79. Manufacturing Cost Structure Analysis of Bispecific Antibody Molecular Drug in 2022
Figure 80. Manufacturing Process Analysis of Bispecific Antibody Molecular Drug
Figure 81. Industry Chain Structure of Bispecific Antibody Molecular Drug
Figure 82. Channels of Distribution
Figure 83. Global Bispecific Antibody Molecular Drug Sales Market Forecast by Region (2024-2029)
Figure 84. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 85. Global Bispecific Antibody Molecular Drug Sales Market Share Forecast by Type (2024-2029)
Figure 86. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 87. Global Bispecific Antibody Molecular Drug Sales Market Share Forecast by Application (2024-2029)
Figure 88. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Application (2024-2029)
Figure 1. Picture of Bispecific Antibody Molecular Drug
Figure 2. Bispecific Antibody Molecular Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bispecific Antibody Molecular Drug Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Bispecific Antibody Molecular Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Bispecific Antibody Molecular Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of EGFR?HER3 Target
Figure 10. Product Picture of PD-1?CTLA-4 Target
Figure 11. Product Picture of HER2?HER3 Target
Figure 12. Global Bispecific Antibody Molecular Drug Sales Market Share by Type in 2022
Figure 13. Global Bispecific Antibody Molecular Drug Revenue Market Share by Type (2018-2023)
Figure 14. Bispecific Antibody Molecular Drug Consumed in Pancreatic Cancer
Figure 15. Global Bispecific Antibody Molecular Drug Market: Pancreatic Cancer (2018-2023) & (K Units)
Figure 16. Bispecific Antibody Molecular Drug Consumed in Breast Cancer
Figure 17. Global Bispecific Antibody Molecular Drug Market: Breast Cancer (2018-2023) & (K Units)
Figure 18. Bispecific Antibody Molecular Drug Consumed in Colorectal Cancer
Figure 19. Global Bispecific Antibody Molecular Drug Market: Colorectal Cancer (2018-2023) & (K Units)
Figure 20. Bispecific Antibody Molecular Drug Consumed in Non-Small Cell Lung Cancer
Figure 21. Global Bispecific Antibody Molecular Drug Market: Non-Small Cell Lung Cancer (2018-2023) & (K Units)
Figure 22. Bispecific Antibody Molecular Drug Consumed in Solid Tumor
Figure 23. Global Bispecific Antibody Molecular Drug Market: Solid Tumor (2018-2023) & (K Units)
Figure 24. Bispecific Antibody Molecular Drug Consumed in Others
Figure 25. Global Bispecific Antibody Molecular Drug Market: Others (2018-2023) & (K Units)
Figure 26. Global Bispecific Antibody Molecular Drug Sales Market Share by Application (2022)
Figure 27. Global Bispecific Antibody Molecular Drug Revenue Market Share by Application in 2022
Figure 28. Bispecific Antibody Molecular Drug Sales Market by Company in 2022 (K Units)
Figure 29. Global Bispecific Antibody Molecular Drug Sales Market Share by Company in 2022
Figure 30. Bispecific Antibody Molecular Drug Revenue Market by Company in 2022 ($ Million)
Figure 31. Global Bispecific Antibody Molecular Drug Revenue Market Share by Company in 2022
Figure 32. Global Bispecific Antibody Molecular Drug Sales Market Share by Geographic Region (2018-2023)
Figure 33. Global Bispecific Antibody Molecular Drug Revenue Market Share by Geographic Region in 2022
Figure 34. Americas Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 35. Americas Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 36. APAC Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 37. APAC Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 38. Europe Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 39. Europe Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 40. Middle East & Africa Bispecific Antibody Molecular Drug Sales 2018-2023 (K Units)
Figure 41. Middle East & Africa Bispecific Antibody Molecular Drug Revenue 2018-2023 ($ Millions)
Figure 42. Americas Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 43. Americas Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 44. Americas Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 45. Americas Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 46. United States Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 47. Canada Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 48. Mexico Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 49. Brazil Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. APAC Bispecific Antibody Molecular Drug Sales Market Share by Region in 2022
Figure 51. APAC Bispecific Antibody Molecular Drug Revenue Market Share by Regions in 2022
Figure 52. APAC Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 53. APAC Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 54. China Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. Japan Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. South Korea Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 57. Southeast Asia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 58. India Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 59. Australia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 60. China Taiwan Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. Europe Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 62. Europe Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 63. Europe Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 64. Europe Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 65. Germany Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 66. France Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 67. UK Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 68. Italy Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 69. Russia Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Country in 2022
Figure 71. Middle East & Africa Bispecific Antibody Molecular Drug Revenue Market Share by Country in 2022
Figure 72. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Type (2018-2023)
Figure 73. Middle East & Africa Bispecific Antibody Molecular Drug Sales Market Share by Application (2018-2023)
Figure 74. Egypt Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 75. South Africa Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 76. Israel Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 77. Turkey Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 78. GCC Country Bispecific Antibody Molecular Drug Revenue Growth 2018-2023 ($ Millions)
Figure 79. Manufacturing Cost Structure Analysis of Bispecific Antibody Molecular Drug in 2022
Figure 80. Manufacturing Process Analysis of Bispecific Antibody Molecular Drug
Figure 81. Industry Chain Structure of Bispecific Antibody Molecular Drug
Figure 82. Channels of Distribution
Figure 83. Global Bispecific Antibody Molecular Drug Sales Market Forecast by Region (2024-2029)
Figure 84. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 85. Global Bispecific Antibody Molecular Drug Sales Market Share Forecast by Type (2024-2029)
Figure 86. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 87. Global Bispecific Antibody Molecular Drug Sales Market Share Forecast by Application (2024-2029)
Figure 88. Global Bispecific Antibody Molecular Drug Revenue Market Share Forecast by Application (2024-2029)
